Preview

Медико-биологические проблемы жизнедеятельности

Расширенный поиск

Особенности вакцинации от COVID-19 у пациентов онкологического профиля

Аннотация

В зарубежных периодических изданиях часто появляются сообщения о высоком риске тяжелых осложнений у онкологических пациентов при развитии COVID-19. В данной статье приведен обзор данных зарубежной литературы, включающий ряд аспектов, отражающих рекомендации по вакцинации против SARS-COV-2 пациентов с онкогематологическими заболеваниями, солидными опухолями, реципиентов гемопоэтических стволовых клеток и клеточной терапии. Несомненно, пациенты онкологического профиля относятся к группе повышенного риска тяжелого течения COVID-19, при этом текущее онкологическое заболевание не допускает задержки в терапии. В связи с этим оказание онкологической помощи во время пандемии COVID-19 стало достаточно сложной задачей, учитывая конкурирующие риски смерти от развивающегося онкологического процесса и серьезные осложнения от течения инфекции COVID-19 у людей с ослабленным иммунитетом. На сегодняшний день не существует официальных рекомендаций по проведению вакцинации против SARS-COV-2 таким пациентам. Ведущими в данном вопросе являются рекомендации зарубежных онкологических сообществ, обзор которых представлен в данной статье.

Об авторах

В. Н. Беляковский
УО «Гомельский государственный медицинский университет»
Россия


В. С. Волчек
УО «Гомельский государственный медицинский университет»
Россия


Список литературы

1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on by 11 February 2020 [Electronic resource]. - Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. - Date of access: 12.02.2020.

2. Yu J. SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China /j. Yu, W. Ouyang, M. Chua, C. Xie // JAMA Oncology. - 2020, №. 6 (7). - Р. 1108-1110. doi.org/10.1001/jamaoncol.2020.0980.

3. Lewis M. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19/ M. Lewis // The New England Journal of Medicine. - 2020. - Vol. 382. - Р. 2285-2287. doi.org/10.1056/nejmp2006588

4. Cannistra S. Challenges Faced by Medical Journals During the COVID-19 Pandemic / S. Cannistra, B. Haffty, K. Ballman // Journal of Clinical Oncology. - 2020. - Vol. 38, № 19. - р. 2206. doi.org/10.1200/jco.20.00858

5. Vaccination against SARS-COV-2 in oncology / A. Polyakov [et al.] // Oncohematology. - 2021. - Vol. 16, № 2. - Р. 70-80. (In Russ.) doi.org/10.17650/1818-8346-2021-16-2-70-80

6. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact sheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144413/download. - Date of access: 21.10.2021).

7. Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19). Factsheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery. - Date of access: 21.10.2021.

8. US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.

9. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee ) [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf. - Date of access: 27.09.2021.

10. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.

11. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine / F. Polack [et al.] // The New England Journal of Medicine. - 2020. - Vol. 383. - Р. 2603-2615. doi.org/10.1056/nejmoa2034577

12. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine / L. Baden [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 403-416. doi.org/10.1056/nejmoa2035389

13. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 /j. Sadoff [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 2187-2201. doi.org/10.1056/nejmoa2101544

14. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients / R. Palich [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1051-1053. doi.org/10.1016/j.annonc.2021.04.020

15. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors /j. Barrière [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1053-1055. doi.org/10.1016/j.annonc.2021.04.019

16. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study / L. Monin [et al.] // The Lancet Oncology. - 2021. - Vol. 22. - Р. 765-778. doi.org/10.1016/s1470-2045(21)00213-8

17. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer / T. Goshen-Lago [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1507-1513. doi.org/10.1001/jamaoncol.2021.2675

18. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients / P. Heudel [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1443-1444. doi.org/10.1016/j.annonc.2021.07.012

19. Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment / N. Eliakim-Raz [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1716-1718. doi.org/10.1001/jamaoncol.2021.4390

20. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer / A. Massarweh [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 8. - Р. 1133-1140. doi.org/10.1001/jamaoncol.2021.2155

21. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients / H. Ligumsky [et al.] // Journal of the National Cancer Institute. - 2021. - Vol. 22, № 7. - Р. 174-149. doi.org/10.1093/jnci/djab174

22. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors / I. Waldhorn [et al.] // Cancer Discovery. - 2021. - № 11. - Р. 2430-2435. doi.org/10.1158/2159-8290.cd-21-1072

23. Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002

24. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies / L. Greenberger [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1031-1033. doi.org/10.1016/j.ccell.2021.07.012

25. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease / T. Ollila [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1714-1716. doi.org/10.1001/jamaoncol.2021.4381

26. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094

27. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations / M. Mair [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1344-1350. doi.org/10.1001/jamaoncol.2021.5437

28. Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002

29. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094

30. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia / Y. Herishanu [et al.] // Blood. - 2021. - Vol. 137, № 23. - Р. 3165-3173. doi.org/10.1182/blood.2021011568

31. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. / L. Roeker [et al.] // Leukemia. - 2020. - № 34. - Р. 3047-3049. doi.org/10.1038/s41375-020-01030-2

32. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases / D. Baker [et al.] // Clinical and Experimental Immunology. - 2020. - Vol. 202, № 2. - Р. 149-161. doi.org/10.1111/cei.13495

33. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? / R. Houot [et al.] // European Journal of Cancer. - 2020. - Vol. 136. - Р. 4-6. doi.org/10.1016/j.ejca.2020.06.017

34. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase / C. Mark [et al.] // Pediatric Blood and Cancer. - 2021. - Vol. 68, № 11. - Р. 292-295. doi.org/10.1002/pbc.29295

35. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature / A. Desage [et al.] // American Journal of Clinical Oncology. - 2021. - Vol. 44, № 3. - Р. 109-113. doi.org/10.1097/coc.0000000000000788

36. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors / B. Waissengrin [et al.] // The Lancet Oncology. - 2021. - Vol. 22, № 5. - Р. 581-583. doi.org/10.1016/s1470-2045(21)00155-8

37. Personal neoantigen vaccines induce persistent memory T-cell responses and epitope spreading in patients with melanoma / Z. Hu [et al.] // Nature Medicine. - 2021. - Vol. 27. - Р. 515-525. doi.org/10.1038/s41591-020-01206-4

38. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks /j. Hwang [et al.] // Journal of Hematology and Oncology. - 2021. - Vol. 14, № 38. - Р. 1045-1046. doi.org/10.1186/s13045-021-01046-w

39. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.

40. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients / V. Hall [et al.] // The New England Journal of Medicine. - 2021. - Vol. 385. - Р. 1244-1246. doi.org/10.1056/nejmc2111462

41. CDC Statement on ACIP Booster Recommendations [Electronic resource]. - Available at: https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html. - Date of access: 26.09.2021.

42. CDC Data and clinical considerations for additional doses in immunocompromised people [Electronic resource]. - Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. - Date of access: 23.07.2021.

43. US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.

44. American Society of Clinical Oncology (ASCO). COVID-19 Vaccine & Patients with Cancer [Electronic resource]. - Available at: https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer. - Date of access: 06.01.2021.

45. update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy / N. Giesen [et al.] // European Journal of Cancer. - 2021. - Vol. 147. - Р. 154-160. doi.org/10.1016/j.ejca.2021.01.033

46. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) / M. Gauci [et al.] // European Journal of Cancer. - 2021. - Vol. 148. - Р. 121-123. doi.org/10.1016/j.ejca.2021.02.003

47. American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases [Electronic resource]. - Available at: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. - Date of access: 04.03.2021.

48. Antibody response after second BNT162b2 dose in allogeneic HSCT recipient / R. Redjoul [et al.] // The Lancet. - 2021. - Vol. 398, № 10297. - Р. 298-299. doi.org/10.1016/s0140-6736(21)01594-4

49. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study / F. Mozaffari [et al.] // Cancer Immunology, Immunotherapy. - 2009. - Vol. 58. - Р. 111-120. doi.org/10.1007/s00262-008-0530-5

50. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer / R. Verma [et al.] // Breast Cancer Research. - 2016. - Vol. 18, № 10. doi.org/10.1186/s13058-015-0669-x

51. Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data / H. Carreira [et al.] //EClinicalMedicine. - 2020. - Vol. 29, № 100656. doi.org/10.1016/j.eclinm.2020.100656


Рецензия

Для цитирования:


Беляковский В.Н., Волчек В.С. Особенности вакцинации от COVID-19 у пациентов онкологического профиля. Медико-биологические проблемы жизнедеятельности. 2022;(1):12-22.

For citation:


Belyakovsky V., Volchek V. FEATURES OF VACCINATION AGAINST COVID-19 IN CANCER PATIENTS. Medical and Biological Problems of Life Activity. 2022;(1):12-22. (In Russ.)

Просмотров: 41


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2074-2088 (Print)